Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Notes Payables (2021 - 2025)

Historic Notes Payables for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to $100000.0.

  • Coeptis Therapeutics Holdings' Notes Payables fell 9356.47% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year decrease of 9356.47%. This contributed to the annual value of $1.1 million for FY2024, which is 2432.83% up from last year.
  • Coeptis Therapeutics Holdings' Notes Payables amounted to $100000.0 in Q3 2025, which was down 9356.47% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Notes Payables peaked at $2.4 million during Q4 2021, and registered a low of $100000.0 during Q3 2025.
  • For the 5-year period, Coeptis Therapeutics Holdings' Notes Payables averaged around $1.3 million, with its median value being $1.4 million (2023).
  • Its Notes Payables has fluctuated over the past 5 years, first surged by 136666.67% in 2023, then crashed by 9356.47% in 2025.
  • Coeptis Therapeutics Holdings' Notes Payables (Quarter) stood at $2.4 million in 2021, then dropped by 23.46% to $1.8 million in 2022, then crashed by 52.7% to $875000.0 in 2023, then increased by 24.33% to $1.1 million in 2024, then plummeted by 90.81% to $100000.0 in 2025.
  • Its last three reported values are $100000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.7 million during Q1 2025.